We've found
45,497
archived clinical trials in
Breast Cancer
We've found
45,497
archived clinical trials in
Breast Cancer
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Updated: 10/1/2015
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
Status: Enrolling
Updated: 10/1/2015
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Updated: 10/1/2015
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Updated: 10/1/2015
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
Status: Enrolling
Updated: 10/1/2015
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Updated: 10/1/2015
Phase I/II Trial of ZD1839 (Iressa®), Trastuzumab (Herceptin®), and Docetaxel (Taxotere®) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Aging and Cancer Effects (ACE) Study
Updated: 10/1/2015
Aging and Cancer: The Effects of Comorbidities on Cancer and it's Treatment
Status: Enrolling
Updated: 10/1/2015
Aging and Cancer Effects (ACE) Study
Updated: 10/1/2015
Aging and Cancer: The Effects of Comorbidities on Cancer and it's Treatment
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Pycnogenol for the Treatment of Lymphedema
Updated: 10/1/2015
Treatment of Arm Lymphedema in Breast Cancer Survivors: A Double-Blind, Randomized Study of Pycnogenol vs. Placebo
Status: Enrolling
Updated: 10/1/2015
Pycnogenol for the Treatment of Lymphedema
Updated: 10/1/2015
Treatment of Arm Lymphedema in Breast Cancer Survivors: A Double-Blind, Randomized Study of Pycnogenol vs. Placebo
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Views on Sharing Family Medical History in Healthy Women Undergoing Mammograms or Breast Evaluation
Updated: 10/1/2015
Patient Perspectives on Sharing Family Medical Histories
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Lapatinib Resistance in Patients With Breast Cancer
Updated: 10/1/2015
Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
Updated: 10/1/2015
A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer
Status: Enrolling
Updated: 10/1/2015
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
Updated: 10/1/2015
A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers
Updated: 10/1/2015
Physiology of Chemotherapy Induced Fatigue and Cognitive Dysfunction in Early Stage Breast Cancer
Status: Enrolling
Updated: 10/1/2015
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers
Updated: 10/1/2015
Physiology of Chemotherapy Induced Fatigue and Cognitive Dysfunction in Early Stage Breast Cancer
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers
Updated: 10/1/2015
Physiology of Chemotherapy Induced Fatigue and Cognitive Dysfunction in Early Stage Breast Cancer
Status: Enrolling
Updated: 10/1/2015
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers
Updated: 10/1/2015
Physiology of Chemotherapy Induced Fatigue and Cognitive Dysfunction in Early Stage Breast Cancer
Status: Enrolling
Updated: 10/1/2015
Click here to add this to my saved trials
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Click here to add this to my saved trials
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Click here to add this to my saved trials
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Click here to add this to my saved trials
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Click here to add this to my saved trials
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
Updated: 10/2/2015
A Phase II Randomised, Double-Blind, Stratified, Multi-Centre Trial Comparing the Nolvadex 20 Mg And Placebo Combination To The Nolvadex 20 Mg and ZD1839 (IRESSA™) 250 MG Combination In Patients With Metastatic Breast Cancer And Estrogen Receptor (ER) and/or Progesterone (PR) Positive Tumours
Status: Enrolling
Updated: 10/2/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Updated: 10/5/2015
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer
Status: Enrolling
Updated: 10/5/2015
Click here to add this to my saved trials